Indivi
- Company typePrivate
- Founded2012
- HeadquartersBasel, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Indivi firmographics
Firmographics- Name
- Indivi
- Legal name
- Indivi AG
- Website
- https://www.indivi.io
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Indivi industry classification
Industry- Product category
- Digital Biomarker Platform for Neuroscience Clinical Trials
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
- akta.pro secondary industry
- Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO)
Keywords
Where Indivi is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Indivi business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Digital biomarker platform licensing and services: Provides digital measurement technology and services to pharmaceutical companies and academic teams conducting neuroscience clinical trials. Revenue derived from licensing technology, providing deployment services, and data processing for clinical trials.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Indivi product offering
Product offeringCore offering
Indivi develops and licenses a smartphone-based digital biomarker platform that transforms any smartphone into a digital measurement laboratory for neurological function assessment in clinical trials. The platform combines dreaMS MD (CE Mark Class I Software Medical Device for MS) and Konectom (licensed from Biogen for Parkinson's disease) to measure motor, cognitive, vision, balance, dexterity, and voice functions, providing end-to-end digital endpoint services from protocol design through regulatory and scientific reporting for pharmaceutical, biotech, and academic research sponsors.
Product overview
Indivi is a TechBio company offering a unified digital biomarker platform for neuroscience research and development. The core offering combines two major smartphone-based technologies: Konectomᵀᴹ (licensed from Biogen) for digital biomarker assessment in Parkinson's disease, and dreaMSᴹᴰ (Indivi's CE-marked medical device) for multiple sclerosis monitoring. The platform measures movement, cognition, vision, balance, dexterity, and voice functions. The technology stack consists of Indivi App (smartphone data capture), Indivi Cloud (real-time secured data transfer with automated quality checks), and Indivi PRO (clinical trial management platform for pharma companies and academia). Through end-to-end digital endpoint development services, the company supports clinical trials from protocol design through regulatory and scientific reporting.
Differentiator
Problem solved
Functional benefit
Brands
- dreaMS MD: CE Mark (Class I) smartphone technology for patients with multiple sclerosis. A Software Medical Device cleared by the European Medicine Agency (EMA) that assesses patients' neurological function during daily activities, focusing on movement, dexterity, cognition, and vision.
- Konectom
Products and services
- dreaMS MD CE Mark (Class I) cleared smartphone-based Software Medical Device for monitoring neurological functions in multiple sclerosis patients, assessing movement, dexterity, cognition, and vision during daily activities. Algorithmically analyzed digital metrics feed clinical trials and patient monitoring. For pharmaceutical sponsors and clinical research organizations.
- Konectom Smartphone-based digital biomarker platform licensed from Biogen for remote assessment of neurological functions in Parkinson's disease clinical trials. Provides precise, frequent measurement of disease evolution including movement, dexterity, cognition, and vision. For pharmaceutical sponsors.
- Indivi PRO Advanced clinical trial management platform for the pharmaceutical industry, clinical research organizations, and academia. Provides end-to-end services throughout clinical trials from protocol design to regulatory and scientific reporting, including adaptive interim analyses, responsive digital measure identification, and statistical analysis.
- Indivi App Unified smartphone data capture system that combines assessments from multiple partner devices and apps, transforming any smartphone into a digital measurement laboratory for precision medicine development.
- Indivi Cloud Secure cloud infrastructure enabling real-time data transfer from the Indivi App with automated data integrity and quality checks, and regulatory-compliant data processing and analysis.
Quantifiable outcome
- Reduced sample size and/or increased probability of success in proof-of-concept trials through higher SNR digital endpoints
- +1 more outcomes
Companies that use Indivi
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Indivi technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
Indivi partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and flagship.
- BiogencoreMulti-year strategic collaboration where Biogen licensed Konectomᵀᴹ to Indivi. Indivi took over digital management of the Phase 2b LUMA study evaluating BIIB122 in early-stage Parkinson's disease. Companies aim to develop and validate novel digital endpoints in Parkinson's disease and explore additional disease areas.
- Clouds of CareflagshipStrategic partnership announced October 2025 combining neuro-electrophysiology with digital health technologies to create unified R&D framework for early-phase treatments in Alzheimer's and Parkinson's disease. Aim to improve drug development success rates by enabling earlier and more definitive signals in clinical trials.
- Herantis PharmacorePartnership announced May 2026 to integrate Indivi's digital biomarker platform into Herantis' Phase 2 proof-of-concept trial of HER-096 for Parkinson's disease. Indivi's platform uses smartphone-based assessments of motor and cognitive function to enable more sensitive detection of treatment-related changes.
- RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel)coreClose research cooperation with RC2NB, an internationally renowned institution embedded in Basel University Hospital and University of Basel. RC2NB specializes in development and integration of innovative tools that comprehensively characterize disease processes in MS and other neuroimmune/neurodegenerative diseases. Co-CEOs are Profs. Cristina Granziera and Ludwig Kappos.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Indivi competitors and assessment
Company assessmentDirect peers
- Koneksa Health: Koneksa Health develops digital biomarker platforms and remote patient monitoring tools for clinical trials across multiple therapeutic areas including CNS and respiratory. It is the most directly comparable peer to Indivi, serving pharma sponsors with smartphone/wearable-based endpoints and validated digital measures.
- VivoSense: VivoSense provides wearable sensor and digital endpoint analytics for clinical trials, with deep focus on neuroscience and rare disease. It competes with Indivi in the smartphone/wearable-derived digital biomarker space serving pharmaceutical sponsors.
- Cambridge Cognition: Cambridge Cognition develops digital cognitive assessments and cloud-based CNS measurement tools sold to pharmaceutical companies and academic researchers. It directly overlaps with Indivi's cognitive assessment and ADAPT-MCI-style cognitive endpoint offerings.
- ActiGraph: ActiGraph manufactures wearable activity monitors and clinical trial digital endpoint solutions used in pharma studies. Indivi and ActiGraph are already technology/integration partners and serve overlapping CNS clinical trial sponsors.
Broad incumbents
- Clario (formerly ERT/Bioclinica): Clario is a large clinical trial technology and eCOA/ePRO vendor serving pharma and biotech across therapeutic areas. It competes with Indivi at the digital endpoint layer but as part of a much broader portfolio of trial technology services.
- Medidata (Dassault Systèmes): Medidata offers EDC, eCOA, and a broad clinical trial technology platform used by major pharma sponsors. It is a broad incumbent that competes with Indivi's Indivi PRO platform for clinical trial endpoint and data management engagements.
- Roche (Digital Health / Roche Pharma): Roche is a major pharma sponsor and has internal digital biomarker and CNS endpoint capabilities. Several Indivi executives are ex-Roche (e.g., CMO, Head of Biostatistics), and Roche represents both a potential customer and a broad incumbent competitor building similar capabilities.
Emerging players
- Evidation Health: Evidation Health generates patient-generated health data and digital biomarkers from smartphones and wearables for research and pharma collaborations. It is an emerging competitor in the digital biomarker measurement space with broader chronic disease focus.
- AiCure: AiCure provides AI-driven digital biomarkers and patient engagement tools for clinical trials, with CNS experience. It overlaps with Indivi at the digital endpoint and trial-monitoring layer, particularly in CNS indications.
Others
- Biogen: Biogen is both a core customer and licensor (Konectom) to Indivi. While not a direct competitor, Biogen's broader digital health ambitions make it a strategic partner/incumbent with overlapping technology interests in CNS digital endpoints.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Indivi social profiles
Digital presenceIndivi compliance and trust
Trust signalCompliance4 records
Indivi financial estimates
Financial estimateRevenue estimate
Valuation estimate
Indivi leadership team
Management profileNumber of profiles
Profiles11 records
Indivi funding detail
Funding detailFunding overview
Funding rounds10 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Indivi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Indivi
What does Indivi do?
Indivi develops and licenses a smartphone-based digital biomarker platform that transforms any smartphone into a digital measurement laboratory for neurological function assessment in clinical trials. The platform combines dreaMS MD (CE Mark Class I Software Medical Device for MS) and Konectom (licensed from Biogen for Parkinson's disease) to measure motor, cognitive, vision, balance, dexterity, and voice functions, providing end-to-end digital endpoint services from protocol design through regulatory and scientific reporting for pharmaceutical, biotech, and academic research sponsors.
Is Indivi a public or private company?
Indivi is a private company. It is classified as venture growth investor backed and is currently operating.
When was Indivi founded?
Indivi was founded in 2012. It employs 51 to 100 people.
Where is Indivi based?
Indivi is headquartered in Basel, Switzerland, in the Europe region.
How does Indivi make money?
One revenue line is on record: digital biomarker platform licensing and services.
Who are Indivi's main competitors?
Direct peers on record are Koneksa Health, VivoSense, Cambridge Cognition and ActiGraph. Broad incumbents are Clario (formerly ERT/Bioclinica), Medidata (Dassault Systèmes) and Roche (Digital Health / Roche Pharma). Emerging players are Evidation Health and AiCure. Biogen is listed as an others.
Does Indivi have an API?
No public API is recorded for Indivi.
What industry is Indivi in?
Indivi's product category is Digital Biomarker Platform for Neuroscience Clinical Trials. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLACAFAO, Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways). Its NAICS code is 334510 and its SIC code is 3845.